Clinical Trials Logo

Keratoconjunctivitis clinical trials

View clinical trials related to Keratoconjunctivitis.

Filter by:

NCT ID: NCT03753893 Completed - Macular Edema Clinical Trials

Ocular Manifestations in Rheumatic Diseases

Start date: May 1, 2013
Phase:
Study type: Observational

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

NCT ID: NCT03731624 Recruiting - Dry Eye Syndromes Clinical Trials

Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

Dry eye disease, ocular graft-versus-host disease (GVHD), and superior limbic keratoconjunctivitis (SLK) are all ocular surface disorders which mostly involve the outer surface of the eye. Many of the ocular surface disorders may result from or be aggravated by the mechanical stress from eyelid blinking. Specifically, SLK is an inflammatory ocular surface disorder characterizing by redundant superior bulbar conjunctiva. Since redundant superior bulbar conjunctiva can cause a significant mechanical force during eyelid blinking, we found that conjunctival resection with Tenon's capsule excision is helpful in relieving the symptoms of SLK patients. Therapeutic contact lens, protecting the ocular surface from the microtrauma between eyelid and ocular surface, is also an effective treatment for severe dry eye disease, ocular GVHD, and SLK. Although shearing force/mechanical stress has been studied in many different tissues and disease entities, the impact of shearing force over ocular surface is still unclear. While the importance of mechanical stress in ocular surface disorder has been reported, the specific molecule involving the pathogenesis is still unknown. Diadenosine polyphosphates are a family of dinucleotides. They can enhance tear secretion and increase corneal wound healing rate from previous reports. Shear-stress stimuli was also noted to be able to induce diadenosine polyphosphates releasing from human corneal epithelium. In addition, mucin, one of the three components of tear film, has been greatly emphasized in the pathogenesis of dry eye disease. There are also some reports about the shearing force compensating the mucin contents in the inflammatory lung/bowel diseases. If diadenosine polyphosphates or mucin indeed play a role in mechanical stress-related ocular surface disorders, it will be a promising therapeutic targeting in the future.

NCT ID: NCT03706443 Completed - Dry Eye Syndromes Clinical Trials

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

Cross-over comparison of lipid layer thickness and dry eye symptoms with two artificial tear formulations.

NCT ID: NCT03652415 Recruiting - Dry Eye Clinical Trials

DRy Eye Outcome and Prescription Study

DROPS
Start date: August 23, 2018
Phase:
Study type: Observational [Patient Registry]

The DRy eye Outcome and Prescription Study (DROPS) is a large observational multicentre study exploring the 'real world' effectiveness of artificial tears in dry eye disease and determinants of efficacy. The aim is to include at least 635 symptomatic dry eye patients who are prescribed artificial tears. All trainees and fellows in London are invited to become collaborators: collaborators are asked to consent patients, assess signs at baseline, and give patients questionnaires at baseline and 4 weeks (for home completion). In tandem, we are conducting a qualitative review of ophthalmologists' prescribing behaviours for dry eye disease.

NCT ID: NCT03616899 Completed - Clinical trials for Kerato Conjunctivitis Sicca

Safety and Efficacy of KPI-121 in Subjects With DED

STRIDE 3
Start date: July 10, 2018
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2 drops instilled in each eye four times daily (QID).

NCT ID: NCT03557203 Recruiting - Clinical trials for Vernal Keratoconjunctivitis

Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis

Start date: June 1, 2018
Phase:
Study type: Observational

To evaluate the therapeutic effects of dermatologic tacrolimus ointment on eyelids to treat refractory vernal keratoconjunctivitis and atopic keratoconjunctivitis.

NCT ID: NCT03555409 Recruiting - Clinical trials for Microsporidial Keratoconjunctivitis

Clinical Feature and Treatment of Microsporidial Keratoconjunctivitis

MKC
Start date: June 1, 2018
Phase:
Study type: Observational

The purpose of this project was to analysis the causes, pathogenesis, diagnostic modalities and treatment outcomes of microsporidial keratoconjunctivitis.

NCT ID: NCT03551639 Withdrawn - Clinical trials for Microsporidial Keratoconjunctivitis

Application of Real-time PCR Platform for Detection of Vittaforma Corneae Among Patients With Microsporidia Keratitis

MK
Start date: January 1, 2016
Phase:
Study type: Observational

Diagnosis of patients with microsporiosis relies on pathological findings as well as laboratory detection of the causative organism. The conventional laboratory diagnosis of microsporiosis relies on microscopic visualization of the characteristic V. Corneae organisms. We develop a fully automated molecular platform for detection of Vittaforma corneae among patients with microsporidia keratitis.

NCT ID: NCT03479853 Completed - Clinical trials for Meibomian Gland Dysfunction

Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE

MEIBO-ROSACEE
Start date: April 2, 2018
Phase:
Study type: Observational

The aim of this study is to describe the clinical, meibographic and interferometric manifestations of phlyctenular keratitis in children.

NCT ID: NCT03464435 Completed - Clinical trials for Vernal Keratoconjunctivitis

A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis

Start date: November 1, 2016
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment. This prospective 6-mouth period study aims to include 20 severe VKC patients who were not responding to conventional treatments. All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. Additionally, 0.1% olopatadine two times daily and preservative-free artificial tears four times daily will be used. After the first month, LE/T will be stopped, with other treatments continued for the last 5 months. Visual acuity and intraocular pressure (IOP) will be measured at enrollment and 1, 2, 3 and 6 months after treatment. Besides, 6 subjective symptoms and 6 clinical signs will be graded at each visit based on a 4-point scale. The primary endpoints are the change in symptoms and objective signs. Treatment failure will be recorded if extra corticosteroids were required.